NZ746544B2 - Analogs of cyp-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation - Google Patents
Analogs of cyp-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation Download PDFInfo
- Publication number
- NZ746544B2 NZ746544B2 NZ746544A NZ74654417A NZ746544B2 NZ 746544 B2 NZ746544 B2 NZ 746544B2 NZ 746544 A NZ746544 A NZ 746544A NZ 74654417 A NZ74654417 A NZ 74654417A NZ 746544 B2 NZ746544 B2 NZ 746544B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- group
- use according
- hydrogen atom
- alkyl
- formula
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 6
- 208000035475 disorder Diseases 0.000 title claims abstract description 6
- 206010029113 Neovascularisation Diseases 0.000 title abstract 4
- 206010061218 Inflammation Diseases 0.000 title abstract 3
- 230000004054 inflammatory process Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 claims description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- 206010067774 Tumour necrosis factor receptor-associated periodic syndrome Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 235000013877 carbamide Nutrition 0.000 claims description 4
- 125000003700 epoxy group Chemical group 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000011594 Autoinflammatory disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- WVOXLKUUVCCCSU-ZPFDUUQYSA-N Pro-Glu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVOXLKUUVCCCSU-ZPFDUUQYSA-N 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 241001122767 Theaceae Species 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 239000007910 chewable tablet Substances 0.000 claims 1
- 229940068682 chewable tablet Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract 2
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs) for use in treating or reducing the risk of developing or preventing: (i) neovascularization and/or (ii) inflammatory disorder, in particular, ophthalmic disorders associated with neovascularization and/or inflammation. and/or (ii) inflammatory disorder, in particular, ophthalmic disorders associated with neovascularization and/or inflammation.
Description
In a first embodiment there is provided use of a compound of the general formula (I): P-E-I (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating, or reducing the risk of developing, or preventing a disorder selected from the group consisting of vasculitis, nephritis, diabetic vasculopathy, diabetic nephropathy, diabetic retinopathy, ischemia reperfusion injury, renal fibrosis, tumor necrosis factor receptor associated periodic syndrome (TRAPS), Graft rejection in transplantation, liver diseases, pancreatitis, atherosclerosis, pulmonary fibrosis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, and auto-inflammatory diseases, wherein P is a group represented by the general formula (II): –(CH ) -O-(CH ) -X (II) 2 n 2 k wherein n is 0 or an integer of from 3 to 8; and k is 0 or 1; X represents CH OH, CH OAc, CH(O) or a group selected from the group consisting of: N NH and ; wherein 2 3 20 21 22 23 R represents -NHR ; -NR R ; -OR ; -(OCH -CH ) -R ; -C -C -heterocyclyl optionally 2 2 i 3 10 substituted with one, two or three substituents independently selected from the group consisting of hydroxyl group, C -C alkoxy, C -C alkyl, and oxo; 1 6 1 6 wherein R represents an aryl group, a heteroaryl group, or a heterocycloalkyl group, wherein the aryl group is optionally substituted with one, two or three substituents independently selected from the group consisting of C -C alkyl, C -C alkoxy and -C(=O)OR ; 1 6 1 6 21 R and R each independently represents a hydrogen atom; a C -C alkyl group which may be substituted with one or more hydroxyl group(s); a C -C cycloalkyl group or together form a C - 3 6 3 C -heterocycloalkyl; R is a hydrogen atom, or a C -C alkyl group; R is -OH; i is an integer of from 1 to 10; 51 R represents a hydrogen atom; a fluorine or chlorine atom; -CF ; -C(=O)OR ; 52 53 54 –NHC(=O)R ; -C(=O)NR R ; or –S(O )OH; R represents a hydrogen atom, or a C -C alkyl group; 52 53 54 R , R and R each independently represents a C -C alkyl group; and X represents an oxygen atom; sulfur atom; or NH; E is a group represented by the general formula (III) or (IV): P 13 (IV) (III) wherein ring A in formula (III) represents a 5-membered or 6-membered carbocyclic ring containing at least one double bond, including an aromatic carbocyclic ring; and L and T each independently represents a ring atom, wherein L and T are adjacent to another; and 12 13 R and R each independently represents a hydrogen atom, a fluorine atom, or hydroxyl group; I is –(CH ) -Y, wherein m is an integer of from 3 to 6, provided that m is an integer of from 3 to 5 when E is a group according to general formula (III); Y represents -U-V-W-(CH ) -(CH ) , wherein p is an integer from 0 to 6; q is 0 or 1; U is absent or 2 p 3 q selected from the group consisting of CH, CH and NR , with the proviso that U is only CH if it forms an epoxy group together with V and W; V is selected from the group consisting of –C(O)-, - C(O)-C(O)-, -O-, and –S-; W is selected from the group consisting of CH, CH and NR with the proviso that W is only CH if it forms an epoxy group together with U and V; or Y represents a group selected from the group consisting of: 41 42 NR R 44 45 46 47 NR R NR R N 48 f R O ; (oxamide) wherein 40 41 43 44 R , R , R , R each independently represents a hydrogen atom, or -C -C alkyl; and 42 45 R , R each independently represents a -C -C alkyl; with the proviso that when X does not comprise a -C(=O)O-motif with the carbonyl carbon in alpha or beta position to the oxygen atom of general formula (II), Y is an oxamide, a carbamate or a carbamide.
Claims (31)
1. Use of a compound of the general formula (I): P-E-I (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating, or reducing the risk of developing, or preventing a disorder selected from the group consisting of vasculitis, nephritis, diabetic vasculopathy, diabetic nephropathy, diabetic retinopathy, ischemia reperfusion injury, renal fibrosis, tumor necrosis factor receptor associated periodic syndrome (TRAPS), Graft rejection in transplantation, liver diseases, pancreatitis, atherosclerosis, pulmonary fibrosis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, and auto-inflammatory diseases, wherein P is a group represented by the general formula (II): –(CH ) -O-(CH ) -X (II) 2 n 2 k wherein n is 0 or an integer of from 3 to 8; and k is 0 or 1; X represents CH OH, CH OAc, CH(O) or a group selected from the group consisting of: N NH and ; wherein 2 3 20 21 22 23 R represents -NHR ; -NR R ; -OR ; -(OCH -CH ) -R ; -C -C -heterocyclyl optionally 2 2 i 3 10 substituted with one, two or three substituents independently selected from the group consisting of hydroxyl group, C -C alkoxy, C -C alkyl, and oxo; 1 6 1 6 wherein R represents an aryl group, a heteroaryl group, or a heterocycloalkyl group, wherein the aryl group is optionally substituted with one, two or three substituents independently selected from the group consisting of C -C alkyl, C -C alkoxy and -C(=O)OR ; 1 6 1 6 20 21 R and R each independently represents a hydrogen atom; a C -C alkyl group which may be substituted with one or more hydroxyl group(s); a C -C cycloalkyl group or together form a C -C -heterocycloalkyl; 3 10 R is a hydrogen atom, or a C -C alkyl group; R is -OH; i is an integer of from 1 to 10; 5 51 R represents a hydrogen atom; a fluorine or chlorine atom; -CF ; -C(=O)OR ; 52 53 54 –NHC(=O)R ; -C(=O)NR R ; or –S(O )OH; R represents a hydrogen atom, or a C -C alkyl group; 52 53 54 R , R and R each independently represents a C -C alkyl group; and X represents an oxygen atom; sulfur atom; or NH; E is a group represented by the general formula (III) or (IV): (IV) (III) wherein ring A in formula (III) represents a 5-membered or 6-membered carbocyclic ring containing at least one double bond, including an aromatic carbocyclic ring; and L and T each independently represents a ring atom, wherein L and T are adjacent to another; and 12 13 R and R each independently represents a hydrogen atom, a fluorine atom, or hydroxyl group; I is –(CH ) -Y, wherein m is an integer of from 3 to 6, provided that m is an integer of from 3 to 5 when E is a group according to general formula (III); Y represents -U-V-W-(CH ) -(CH ) , wherein p is an integer from 0 to 6; q is 0 or 1; U is 2 p 3 q absent or selected from the group consisting of CH, CH and NR , with the proviso that U is only CH if it forms an epoxy group together with V and W; V is selected from the group consisting of –C(O)-, -C(O)-C(O)-, -O-, and –S-; W is selected from the group consisting of CH, CH and NR with the proviso that W is only CH if it forms an epoxy group together with U and V; or Y represents a group selected from the group consisting of: 41 42 NR R 44 45 46 47 N NR R NR R O ; ; (oxamide) wherein 40 41 43 44 R , R , R , R each independently represents a hydrogen atom, or -C -C alkyl; and 42 45 R , R each independently represents a -C -C alkyl; with the proviso that when X does not comprise a -C(=O)O-motif with the carbonyl carbon in alpha or beta position to the oxygen atom of general formula (II), Y is an oxamide, a carbamate or a carbamide.
2. The use according to claim 1, with the proviso that when n is 0, k is 1.
3. The use according to claim 1 or 2, wherein k is 1.
4. The use according to any one of claims 1 to 3, wherein X is . 12 13
5. The use according to any one of claims 1 to 4, wherein R and R are in a cis configuration.
6. The use according to any one of claims 1 to 5, wherein Y is an oxamide as defined in claim 1.
7. The use according to claim 1, with the proviso that when n is 3 or 5, k is 1 and E is a group according to general formula (III) or general 12 13 formula (IV), wherein each of R and R is a hydrogen atom; P represents a group: 81 81 –(CH ) -O-(CH )-X ; –(CH ) -O-(CH )-X ; 2 3 2 2 5 2 wherein X represents a group selected from the group consisting of: 2' 3' 22' 23 R represents -NHR ; -OR ; -(OCH -CH ) -R ; 2 2 i wherein R represents C6-aryl; R is a hydrogen; and R and i are as defined in claim 1.
8. The use according to claim 1 or 7, wherein X is 2 22 23 wherein R is -OR ; -(OCH -CH ) -R ; 2 2 i wherein i is as defined in claim 1; and 22 23 wherein R , and R are as defined in claim 1.
9. The use according to any one of claims 1, 7, and 8, wherein X is -C(=O)OH or a suitable salt of the carboxylic acid.
10. The use according to claim 9, wherein X is -C(=O)OH.
11. The use according to any one of claims 1, 7, 8, and 9, wherein Y is one of the oxamides defined according to claim 1.
12. The use according to any one of claims 1, 7, 8, and 11, wherein X is 2 22 23 wherein R is -OR ; or -(OCH -CH ) -R ; 2 2 i 22 23 27 wherein R , R to R and i are as defined in claim 1, and wherein Y is one of the oxamides defined according to claim 1.
13. The use according to any one of claims 1, 7, 8, 9, 11, and 12, wherein X is C(=O)OH, preferably the free carboxylic acid, and Y is one of the oxamides defined according to claim 1.
14. The use according to claim 1, wherein the compound is a compound of formula (V), or a pharmaceutically acceptable salt thereof, 57 58 formula (V) wherein 55 22 23 R represents -OH; -OR ; -(OCH -CH ) -R ; and 2 2 i 22 23 R , R and i are as defined in claim 1; Y represents a group selected from the group consisting of: 41 42 NR R 44 45 46 47 N NR R NR R N 48 f R O ; ; (oxamide) 49 49 40 50 wherein R to R are defined in claim 1; 57 58 R and R are hydrogen; f is an integer of from 1 to 2; s is 0, 1 or 2; and the double bond in formula (V) represents a double carbon-carbon bond in cis- 57 58 configuration, if R and R are hydrogen.
15. The use according to claim 14, wherein R is a hydrogen atom or a C -C alkyl group.
16. The use according to claim 14 or 15, wherein R is a hydrogen atom.
17. The use according to any one of claims 14 to 16, wherein i is from 2 to 4.
18. The use according to any one of claims 14 to 17, wherein i is 3.
19. The use according to any one of claims 14 to 18, wherein R is a hydrogen atom or a C -C alkyl group.
20. The use according to any one of claims 14 to 29, wherein R is a hydrogen atom.
21. The use according to claim 14, wherein 55 23 R represents –OH or-(OCH -CH ) -R ; i is 2 to 4; 2 2 i Y is an oxamide, a carbamide or a carbamate; and 57 58 R and R are both H.
22. The use according to claim 21, wherein i is 3.
23. The use according to claim 21 or 22, wherein R is OH.
24. The use according to claim 21, wherein Y is a C -C alkyl substituted oxamide, carbamide or carbamate.
25. The use according to claim 1, wherein the compound is selected from the group consisting of: O OH NH O NH NH O and pharmaceutically acceptable salts thereof.
26. The use according to claim 1, wherein the compound is a compound of formula (VI) O NH NH O formula (VI) or a pharmaceutically acceptable salt thereof.
27. The use according to any one of claims 1 to 26, wherein the disorder is familial Mediterranean fever.
28. The use according to any one of claims 1 to 27, wherein the medicament is adapted for oral, topical, subcutaneous, intramuscular, intravenous, intranasal, or intraocular administration.
29. The use according to any one of claims 1 to 27, wherein the medicament is adapted for oral or intraperitoneal administration.
30. The use according to claim 29, wherein the medicament is adapted for oral administration.
31. The use according to any one of claims 1 to 29, wherein the medicament is a dosage form selected from the group consisting of a spray, an aerosol, a foam, an inhalant, a powder, a tablet, a capsule, a soft gelatin capsule, a tea, a syrup, a granule, a chewable tablet, a salve, a cream, a gel, a suppository, a lozenge, a liposome composition and a solution suitable for injection. OMEICOS Therapeutics GmbH Max Delbrück-Centrum für Molekulare Medizin By the Attorneys for the Applicant SPRUSON & FERGUSON Per:
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317253P | 2016-04-01 | 2016-04-01 | |
| US62/317,253 | 2016-04-01 | ||
| EP17153412 | 2017-01-26 | ||
| EP17153412.6 | 2017-01-26 | ||
| PCT/EP2017/057830 WO2017168007A1 (en) | 2016-04-01 | 2017-04-03 | Analogs of cyp-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ746544A NZ746544A (en) | 2021-10-29 |
| NZ746544B2 true NZ746544B2 (en) | 2022-02-01 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2689984C2 (en) | Cataplexis treatment | |
| KR101605151B1 (en) | Sigma ligands for the prevention or treatment of pain induced by chemotherapy | |
| US20190169113A1 (en) | Ketamine Derivatives | |
| US9034848B2 (en) | Phenyl carbamate compounds for use in preventing or treating stroke | |
| US9226910B2 (en) | Treatment for obesity | |
| AU2003208538B2 (en) | Amino acids with affinity for the alpha-2-delta-protein | |
| BG108182A (en) | Fused bicyclic or tricyclic amino acids | |
| DE4226043A1 (en) | Agents with a physiological cooling effect and active compounds suitable for these agents | |
| ES2784703T3 (en) | Derivatives of pyrrolidine carboxamide and methods for preparing and using the same | |
| BR112013000050A2 (en) | composed of phenyl carbamate and muscle relaxant containing the same | |
| RU2730512C2 (en) | New derivatives of cyp-eicosanoids | |
| NZ746544B2 (en) | Analogs of cyp-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | |
| NZ746544A (en) | Analogs of cyp-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | |
| CA3016180A1 (en) | Prevention, treatment and reversal of disease using therapeutically effective amounts of dicarboxylic acid compounds | |
| CA2539976A1 (en) | Therapeutic beta aminoacids | |
| ES2388253B1 (en) | Sigma ligands for the prevention or treatment of chemotherapy-induced pain | |
| CN114340612A (en) | Composition for preventing or treating asthma, rhinitis or conjunctivitis comprising N-acylamino acid as active ingredient | |
| WO2021002352A1 (en) | Composition for treating or preventing tardive dyskinesia, and method for screening active ingredient for treating or preventing tardive dyskinesia | |
| ES2384852B1 (en) | HYDROXYTIROSOL ETHERS | |
| NZ739273B2 (en) | Metabolically robust analogs of cyp-eicosanoids for the treatment of cardiac disease | |
| NZ739273A (en) | Metabolically robust analogs of cyp-eicosanoids for the treatment of cardiac disease | |
| ZA200601389B (en) | Amino acids with affinity for the alpha2delta-protein | |
| NZ619257B2 (en) | Ketamine derivatives |